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Abstract Background The use of short and uniform centrifugation schemes contributes
signiﬁcantly to the successful automation of laboratory procedures. It is however
unclear if this is applicable to the hemostasis laboratory.
Objectives This article assesses the accuracy of measurements obtained with a rapid,
high-speed centrifugation scheme in a large set of hemostasis tests, covering the full
spectrum of values obtained in clinical practice, and using meaningful statistical
measures.
Methods Two citrated plasma samples were obtained from consecutive patients of a
tertiary hospital with suspected abnormal hemostasis tests and processed with two
centrifugation schemes in parallel: 1,500 g for 10minutes and 3,137 g for
7minutes. The following tests were conducted: prothrombin time (n¼125), interna-
tional normalized ratio (n¼146), activated partial thromboplastin time (n¼119),
thrombin time (n¼105), ﬁbrinogen (n¼125), factor (F)II (n¼69), FV (n¼64), FVII
(n¼64), FX (n¼ 67), FVIII (n¼55), FIX (n¼ 37), FXI (n¼35), and FXIII (n¼20), D-dimer
(n¼34), antithrombin (n¼ 31), anti-Xa activity (n¼ 30), von Willebrand antigen
(n¼25), and von Willebrand activity (VWF:GPIbM; n¼ 27).
Results Awide range of results were obtained in all tests. Spearman’s rank correlation
coefﬁcient was at least 0.95 for all tests except FV, FIX, and FXI. The coverage
probability π at a given deviation index κ of 15% was above 0.9 for all tests except
FV, FVII, FX, FVIII, FIX, FXI, and VWF:GPIbM, suggesting a lack of agreement.
Conclusion Our results suggest that high-speed centrifugation is applicable to the
majority of routine hemostasis parameters. The coverage probability was more
sensitive than Spearman’s rank correlation to detect disagreement among centrifuga-
tion schemes.
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Introduction
Total laboratory automation (TLA) is seen as an important
strategy to tackle today’s challenges in laboratory medicine
and related health care.1–6 Integrating diverse analyzers of
multiple specialities aswell aspreanalytic and sortingmodules
to one track can replacemanymanual tasks and save labor.4,5,7
TLA can save a relevant amount of long-term health care costs
despite high initial investments.8 The efﬁciency can be
improved by reducing the turnaround time (TAT) and increas-
ing the throughput.9,10 Risky and laborious manual sample
managementcanbeavoidedbyalgorithms identifying samples
and triggering rerun or reﬂex tests, thus improving accuracy of
results.4 Controlling all phases of the analytical process using
software programs run centrally enhances standardization,
supports accreditation procedures, and improves quality in
general.4 One important requirement for the integration of
analyzers and specialities intoTLA is uniform and ideally rapid
centrifugationschemes.Thismightpreventdelayof sampleson
the track and improve total TAT.
It is however uncertain whether rapid centrifugation
schemes—used in clinical chemistry as well as immuno-
chemistry—can be applied in the hemostasis laboratory.
Coagulation-based assays are considered to be inﬂuenced
by many preanalytic factors.11 The residual platelet count
after centrifugation is regarded as the most important inﬂu-
encing factor12 and the platelet count is subject to the
centrifugal forces applied.13 Mechanical stimulation is
discussed as a contributing factor as well.14 Some authors
recommend avoiding centrifugal forces above 1,500 g15 but
others do not.16,17 Several scientiﬁc societies in the United
States (Clinical and Laboratory Standards Institute [CLSI]18),
France (Groupe d’Etude sur l’Hémostase et la Thrombose19),
and the United Kingdom (British Committee for Standards in
Haematology20) as well as other authors11 have released
guidance documents and recommend centrifugation
schemes that aim to achieve a platelet count below
1010^9/L using 1,500 g for 10 to 15minutes. Whether
this can be accelerated using higher centrifugal forces
remains unclear. Limitations of previous investigations
include (1) a limited number of patients or samples, (2) a
paucity of hemostasis tests studied, (3) a very limited
spectrum of test results covered (normal only), (4) nonstan-
dard centrifugation schemes as comparators, and (5) use of
insensitive statistical measures.
With the present study, we aimed to comprehensively
assess the accuracy of a rapid, high-speed centrifugation
scheme compared with an established and recommended
centrifugation scheme in a comprehensive set of hemostasis
tests, covering a large spectrum of values, and using mean-
ingful statistical measures.
Methods
Study Design, Setting, and Population
This prospective cohort study was conducted in a university
hospital (Inselspital, Bern University Hospital, Bern,
Switzerland) between October 2015 and March 2016. We
included consecutive patients from a variety of departments
(cardiovascular surgery, internal medicine, intensive care unit,
and hemophilia outpatient unit). The inclusion criterion was
“suspected abnormal hemostasis laboratory test result” to
obtain a sample set covering a broad spectrum of results.
Exclusion criteria were an age below 18 years and refused
general consent. Patients were screened by treating physicians
in the respective departments. The protocol was approved by
the local ethics committee (Kantonale Ethikkommission Bern;
March 18, 2014) and all patients signed the general consent of
the hospital.
Collection and Handling of Samples
An in-house protocol for blood drawing was implemented at
our institution to ensure adequate preanalytic conditions.18
Plasma samples were collected after ethylenediaminetetra-
acetic acid (EDTA) and serum samples to avoid contamination
with residual heparin or tissue factor if bloodwas accidentally
obtained from a vascular access device or using a butterﬂy
needle.12,19,21 Venous blood was drawn into two plastic
syringes of 4.5mL containing 0.106mol/L trisodium citrate
(Monovette, Sarstedt, Nümbrecht, Germany). Samples were
transported immediately to the central laboratory and
the handling of both samples was identical.
Centrifugation Schemes
Both plasma samples were centrifuged within 15minutes
after arrival in the laboratory. The established standard
centrifugation scheme in our institution was 1,500 g for
10minutes (established after determining residual platelet
count in 30 samples).11,19,20 The high-speed centrifugation
scheme was deﬁned as 3,137 g for 7minutes (3,137 g is
the established speed in clinical chemistry at our institution
and the time of 7 minutes was chosen after conducting a
pilot study analyzing residual platelet concentration). Z500
centrifuges were used (HERMLE Labortechnik GmbH,
Wehingen, Germany), implemented in aGLP laboratory track
(GLP Systems GmbH, Hamburg, Germany). The centrifuges
work at 20°C using a brake. After centrifugation, samples
were transferred into aliquots and snap-frozen at –20°C.
Samples were transferred to –80°C if not analyzed within 1
to 2 weeks. All hemostasis parameters were determined
within 2 months following centrifugation.
Determination of Laboratory Assays
Platelet count was analyzed using an automated hematology
analyzer (Coulter Counter LH750, Beckman-Coulter Inc., Nyon,
Switzerland). Prothrombin time was measured using Dade
Innovin reagent (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany) on a Sysmex CS 5100 analyzer
(distributed by Siemens Healthcare Diagnostics Products
GmbH) and expressed as prothrombin ratio (PR, %). Activated
partial thromboplastin time (aPTT) was determined using
Pathrombin SL (Siemens Healthcare Diagnostics Products
GmbH) on a Sysmex CS 5100. Thrombin time was determined
using Thromboclotin reagent (Siemens Healthcare Diagnostics
Products GmbH) on a Sysmex CS 5100. D-dimers were
measured immunoturbidimetrically by Innovance D-Dimer
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(Siemens Healthcare Diagnostics Products GmbH) on a Sysmex
CS 5100. Functional antithrombin activity was determined
using INNOVANCEAntithrombin (SiemensHealthcareDiagnos-
tics Products GmbH) on a Sysmex CS 5100. Fibrinogen was
assessed in plasma by the Claussmethod using Dade Thrombin
Reagent (SiemensHealthcare Diagnostics Products GmbH) on a
Sysmex CS 5100. Factor (F)II, FV, FVII, and FXweremeasured by
a one-stage coagulometric assay usingDade Innovin and factor-
deﬁcient plasma (Siemens Healthcare Diagnostics Products
GmbH) on a Sysmex CS 5100. FVIII, FIX, and FXI were deter-
minedusing a one-stage coagulometric assayusing Pathrombin
SL and factor-deﬁcient plasma on a Siemens BCS XP analyzer
(Siemens Healthcare Diagnostics Products GmbH). FXIII was
analyzed chromatographically using Berichrom Factor XIII test
kit (Siemens Healthcare Diagnostics Products GmbH) on a
Siemens BCS XP. von Willebrand factor antigen (VWF:Ag) was
determined using the VWF Ag Testkit (Siemens Healthcare
Diagnostics Products GmbH) and activity (VWF:GPIbM) using
Siemens Innovance VWF Ac (Siemens Healthcare Diagnostics
Products GmbH). Chromogenic anti-Xa activity for monitoring
unfractionated heparin (UFH) as well as low molecular weight
heparin (LMWH) was determined using BIOPHEN Heparin
LRT (HYPHEN BioMed, Neuville-sur-Oise, France) on a Sysmex
CS 5100.
To contextualize thesemeasurements, we determined the
within-run and day-to-day imprecision in two samples (one
with results in the normal range [n] and one with results in
the abnormal range [p]), 10 times each.
Statistical Analysis
Median (interquartile range, IQR) and numbers (percentages)
were used for descriptive purposes. To analyze concordance
between the two centrifugation schemes, we determined
the Spearman’s rank correlation coefﬁcient as well as the
coverage probability (CP π). The CP π outlines agreement
with several advantages comparedwithmore traditionalmeas-
ures: the computation is simple, discordantmeasurements can
be identiﬁedrapidly, the interpretation is intuitive, anditcanbe
applied to continuous as well as categorical data in a broad
spectrum of observers and populations.22 The CP π can be
interpreted as the proportion of observations falling within
the paired absolute difference κ, a priori deﬁned as acceptable
(the tolerable total deviation index, TDI). In our study, we
deﬁned a TDI of 0.15 as acceptable. The tolerable CP π was
assumed at 0.9. Bland–Altman difference plots for determina-
tionofbias aswell as lowerandhigher limitsofagreementwere
additionally created. Coefﬁcients of variation were calculated
for within-run and day-to-day imprecision. Analyses were
restricted to observations in a meaningful range: PR, 0 to
110%; internationalnormalizedratio (INR), 0.9 to5.0; thrombin
time, 10 to70 seconds; aPTT, 15 to100 seconds;ﬁbrinogen, 0 to
6.0g/L; D-dimer, 0 to 2,000 µg/L; antithrombin, 0 to 120%; FII,
FV, FVII, FX: 0 to 120%; FVIII, FIX, FXI, FXIII: 0 to 200%; andVWF:
GPIbM and VWF:Ag: 0 to 200%. In addition, LMWH measure-
ments below 0.1 U/mL and D-dimer below 400 U/mL were
censored for CP measurements. The Stata 14.1 statistics soft-
ware package (StataCorp. 2015; Stata Statistical Software:
Release14.2, StataCorp LP, College Station, Texas,UnitedStates)
as well as R (R Development Core Team [2008]; R: A language
and environment for statistical computing; R Foundation for
Statistical Computing, Vienna, Austria; ISBN 3–900051–07–0,
http://www.R-project.org) were used for statistical analyses.
Figureswere createdusing Prism6 (GraphPadSoftware, Inc., La
Jolla, California, United States).
Results
Patients
Samples from 198 patients were analyzed, the ﬂow is
illustrated in ►Fig. 1. Seventy-four patients were recruited
from hematology outpatient unit (37%), 51 patients from
intensive care unit (26%), 48 patients from general internal
medicine (24%), and 25 patients from the surgery depart-
ment (13%). The median age of the patients was 56.0 years
(range: 19.7–94.4) and 47.5% were female (n¼94). The
number of observations per test is shown in ►Table 1. The
range of values is reported in ►Table 1, the distribution is
illustrated in scatterplots (►Supplementary Figs. S1–S3,
available in the online version).
Platelet count
The median platelet count in plasma after centrifugationwith
3,137 g for 7minutes was 810^9/L (IQR: 4–1210^9/L;
n¼30). Platelet count was 610^9/L (IQR: 3–9; n¼30) in
samples centrifuged at 1,500 g for 10minutes.
Concordance between Centrifugation Schemes
All results are reported in detail in►Table 1. Scattergrams of
PR, aPTT, ﬁbrinogen, and D-dimer are shown as an example
in ►Fig. 2. Scattergrams and Bland–Altman difference plots
for all tests are shown in►Supplementary Figs. S1–S3 (avail-
able in the online version). ►Fig. 3 summarizes the accuracy
of all tests and contrasts rs to CP estimates.
With regard to the routine parameters PT, INR, thrombin
time, and aPTT, correlation (rs) was clearly above 0.95 and CP
π above 0.9 (►Table 1). Bias and limits of agreement of the
Bland–Altman difference plot were close to zero. According-
ly, coefﬁcient of variation (CV) was below 5% with regard to
within-run and day-to-day imprecision (day-to-day impre-
cision of the abnormal sample: 6.7%).
Similar results were observed with regard to ﬁbrinogen,
D-dimer, and antithrombin activity measurements: rs was
above 0.95, CP π above 0.9, and Bland–Altman estimates
close to zero. CV was below 5% (except within-run impreci-
sion of the normal D-dimer sample: 12.0%).
Anti-Xa activitymeasurements (UFHand LMWH) resulted
in rs above 0.95 and a CP π above 0.9 as well. Bland–Altman
estimates were close to zero and CV was below 5% (except
day-to-day imprecision of LMWH-measurements: 5.9%).
Correlation (rs) was above 0.95 and CP π above 0.9 for VWF:
Ag but not for VWF:GPIbM (0.76; 95% conﬁdence interval:
0.59–0.89). Accordingly, the lower limit of agreement was
–18.1, and thehigher limitofagreementwas10 forVWF:GPIbM.
Within-run as well as day-to-day imprecision was below 5%.
A borderline rs was observed for FV (92%), FVII (95%), and
FX (95%), the CP π was clearly below 0.9 (see ►Table 1).
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Accordingly, the agreement interval of the Bland–Altman
plot was wide. With regard to FII, rs was 0.97 and CP π 0.95.
Within-run as well as day-to-day imprecision was low
(CV< 5% for FVII, and<10% for FII, FV, and FX).
In thecaseofFVIII, rswas0.96butCPπwas0.30; rswasbelow
0.95 and CP π below 0.9 in the case of FIX as well as FXI. The
agreement interval of the Bland–Altman plot was wide
(►Table 1). Within-run as well as day-to-day imprecision was
below 10%.
With regard to FXIII, rs was 0.96 and CP π 0.96; CV was
below 10%.
Discussion
In the present study, we tested the accuracy of measure-
ments obtained with rapid, high-speed centrifugation
scheme studying a large spectrum of hemostasis tests and
covering the full range of values obtained in clinical practice.
Fig. 1 Sample ﬂow.
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CP π identiﬁedmore assays with nonconcordant results than
Spearman’s correlation coefﬁcient. Whereas an appropriate
concordance between measurements were observed for all
routine parameters, relevant discrepancies were observed
with regard to most single-factor determinations as well as
VWF:GPIbM.
Our observations and data reported here are in line with
the limited data published to date on this topic. Lippi et al
compared samples obtained in 15 healthy volunteers and
centrifuged with 3,000 g versus 1,500 g. Signiﬁcant dif-
ferences were found with regard to FVIII and IX, but not for
PT, aPTT, or ﬁbrinogen.13 Several routine tests (ﬁbrinogen,
Table 1 Concordance results of routine hemostasis measurements obtained with a rapid, high-speed centrifugation scheme in
comparison to a traditional scheme
Parameter Obs. Results Correlation
coefficient
Coverage
probability πa
Bland–Altman difference plot Analytical
variabilityb
rs Bias LLA HLA Within-run
imprecision
Day-to-day
imprecision
Numbers Median
(range)
(95% CI) (95% CI) (95% CI) (CV in %) (CV in %)
PR (%) 125 78.5
(6.6, 107.8)
0.99
(0.98, 0.99)
0.99
(0.84, 1.00)
0.2
(–0.3, 0.7)
–5.6 6.0 0.6 (n)
0.8 (p)
4.0 (n)
2.2 (p)
INR 146 1.04
(0.9, 3.5)
0.99
(0.99, 0.99)
1.00
(0.96, 1.00)
0.0
(–0.0, 0.0)
–0.2 0.2 0.7 (n)
0.9 (p)
4.2 (n)
2.4 (p)
Thrombin
time (s)
105 16.5
(13.2, 57.3)
0.97
(0.95, 0.98)
1.00
(1.00, 1.00)
–0.1
(–0.3, 0.0)
–1.6 1.4 2.0 (n)
2.9 (p)
2.2 (n)
2.6 (p)
aPTT (s) 119 34.9
(22.0, 96.0)
0.99
(0.99, 0.99)
1.00
(1.00, 1.00)
0.0
(–0.2, 0.2)
–2.1 2.1 0.6 (n)
1.1 (p)
1.8 (n)
6.7 (p)
Fibrinogen
(g/L)
125 2.3
(0.0, 5.8)
0.98
(0.97, 0.99)
0.96
(0.91, 0.99)
–0.0
(–0.0, 0.0)
–0.3 0.3 1.2 (n)
1.1 (p)
3.2 (n)
6.0 (p)
D-dimer
(µg/L)
34 395
(17, 1970)
0.99
(0.99, 1.00)
1.00
(0.99, 1.00)
13.4
(3.5, 23.4)
–43.4 70.3 12.0 (n)
2.0 (p)
3.0 (n)
2.0 (p)
Antithrombin
(%)
31 76.6
(40.4, 108.5)
0.99
(0.99, 1.00)
1.00
(0.99, 1.00)
0.2
(–0.7, 1.1)
–4.7 5.1 1.3 (n)
2.8 (p)
1.1 (n)
2.2 (p)
Anti-Xa activity
(UFH; U/mL)
30 0.10
(0.01, 0.92)
0.99
(0.98, 1.00)
0.94
(0.86, 0.99)
0.00
(–0.01, 0.01)
–0.03 0.03 2.1 (p) 3.8 (p)
Anti-Xa activity
(LMWH; U/mL)
27 0.06
(0.00, 0.51)
0.99
(0.97, 0.99)
0.93
(0.77, 1.00)
0.00
(–0.01, 0.01)
–0.03 0.03 1.7 (p) 5.9 (p)
Factor II (%) 69 84.0
(16.0, 119.0)
0.97
(0.96, 0.98)
0.95
(0.81, 1.00)
0.6
(–0.6, 1.8)
–9.2 10.4 1.4 (n)
1.9 (p)
1.8 (n)
6.9 (p)
Factor V (%) 64 85.0
(0.0, 120.0)
0.92
(0.86, 0.95)
0.41
(0.20, 0.65)
–1.6
(–4.3, 1.1)
–23.3 20.2 2.2 (n)
2.4 (p)
4.1 (n)
5.2 (p)
Factor VII (%) 64 65.3
(15.0, 120.0)
0.95
(0.92, 0.97)
0.57
(0.36, 0.84)
–1.1
(–3.2, 0.9)
–17.5 15.3 1.6 (n)
3.4 (p)
2.9 (n)
3.3 (p)
Factor X (%) 67 75.1
(5.0, 118.8)
0.95
(0.91, 0.97)
0.60
(0.46, 0.74)
–0.4
(–2.4, 1.7)
–17.2 16.5 1.9 (n)
1.4 (p)
3.0 (n)
5.6 (p)
Factor VIII (%) 55 79.5
(0.3, 198.0)
0.96
(0.93, 0.98)
0.30
(0.21, 0.38)
–17.5
(–22.3, –12.7)
–53.0 17.9 2.8 (n)
2.3 (p)
5.5 (n)
4.0 (p)
Factor IX (%) 37 104.0
(15.0, 138.0)
0.84
(0.70, 0.91)
0.79
(0.61, 0.90)
–0.9
(–4.5, 2.7)
–22.5 20.7 1.9 (n)
2.1 (p)
3.3 (n)
6.2 (p)
Factor XI (%) 35 96.0
(47.0, 163.0)
0.79
(0.61, 0.89)
0.80
(0.68, 0.90)
–1.3
(–4.8, 2.2)
–21.6 19.0 3.1 (n)
1.8 (p)
2.6 (n)
7.3 (p)
Factor XIII (%) 20 110.5
(15.1, 162.0)
0.96
(0.89, 0.98)
0.96
(0.82, 0.99)
–2.5
(–5.9, 1.0)
–17.0 12.1 3.2 (n)
2.0 (p)
5.6 (n)
3.8 (p)
VWF:Ag (%) 25 87.0
(12.0, 191.3)
0.99
(0.97, 0.99)
0.96
(0.83, 0.99)
–1.2
(–2.9, 0.5)
–9.4 7.0 1.7 (n)
2.4 (p)
1.9 (n)
4.1 (p)
VWF:GPIbM
(%)
27 84.0
(7.0, 178.9)
0.98
(0.95, 0.99)
0.76
(0.59, 0.89)
–3.8
(–6.6, –1.0)
–18.1 10.4 1.7 (n)
1.6 (p)
2.2 (n)
2.7 (p)
Abbreviations: aPTT, activated partial thromboplastin time; CV, coefﬁcient of variation; HLA, higher limit of agreement; INR, international
normalized ratio; LLA, lower limit of agreement; LMWH, low molecular weight heparin; Obs., observations; PR, prothrombin ratio; rs, Spearman’s
rank correlation coefﬁcient; UFH, unfractionated heparin; VWF:Ag, von Willebrand factor antigen; VWF:GPIbM, von Willebrand factor functional
activity as measured using the spontaneous binding of VWF to a gain-of-function mutant GPIb fragment.
aBased on an accepted total deviation index of 0.15.
bObtained in two samples, one with results in the normal range [n] and one with results in the abnormal range [p], 10 times each.
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INR, aPTT, D-dimer) as well as single factors have also been
studied (1,500 g for 5minutes vs. 3,000 g for 7minutes)
in a limited number of patients with mostly normal test
results and a correlation coefﬁcient of all routine tests aswell
as most factors studies was above 0.9.23 Suchsland et al have
compared PT, aPTT, FVIII, and protein S in one versus two
runs of 3,280 g for 5minutes. The outcome of that work
reported a correlation coefﬁcient above 0.9 for all but protein
S.24 Boissier et al17 compared a centrifugal spin protocol of
4,500 g for 2minutes to a 2,200 g for 15minutes protocol
in 200 patients in the following assays PT, INR, aPTT, ﬁbrino-
gen, thrombin time, FII, FV, antithrombin, and anti-Xa
activity.17 These authors concluded that the agreement
was adequate. We have also essentially repeated the Boissier
centrifugation protocols in samples of patients treated with
direct oral anticoagulations and measurements of anti-Xa
activity, and we have arrived at similar conclusions.16 In
another study, PT, aPTT, and INR measurements were com-
pared in platelet-poor plasma and platelet-rich plasma of 100
samples, and again found to be similar.21
Strengths and Limitations/Implications
In contrast to previous studies, we have studied a broad range
of hemostasis tests covering the full spectrum of test results
in a large number of patients recruited in clinical practice. In
addition, an established centrifugation schemewas used, and
sensitive statistical measures were applied. Thus, our results
aremeaningful and are applicable to routine clinical practice.
Our study nevertheless has several limitations. First, lupus
anticoagulant and other tests used in clinical practice were
not studied, and our results can therefore not be extrapolated
to these tests. Second, even though our routine centrifugation
scheme (1,500 g for 10minutes), which was used as com-
parator, was tested according to the CLSI guidelines, most
institutions are known to use a 15-minute scheme instead.
We cannot fully exclude that this might have affected our
results. Third, only one centrifugewas tested, andwehave not
excluded that different results might have been obtained
using alternative centrifuges. Thus, future investigations
will seek to conﬁrm our results in various settings using
different centrifuges as well. Forth, citrated samples were
Fig. 2 Concordance of routine hemostasis measurements obtained with a rapid, high-speed centrifugation scheme in comparison to a
traditional scheme. Scattergrams of prothombin ratio (PR, %), activated partial thromboplastin time (aPTT, seconds), ﬁbrinogen (Clauss
method; g/L), and D-dimer (µg/L) are shown as an example, all other results are shown in the Supplementary Material. Spearman’s rank
correlation coefﬁcient (rs) is reported.
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collected after EDTA samples andwe cannot fully exclude that
residual EDTA might have inﬂuenced the results. We believe
that the risk of a bias is low because the tubes were applied to
the centrifugation schemes randomly and previous studies
did not demonstrate a relevant difference of standard coagu-
lation test results.25 Fifth, for reasons of practicability not all
pairs of samples were analyzed within the 2-week interval
recommended bycurrent guidelines but were transferred to a
–80°C freezer after several days and analyzed within
2 months. However, all pairs were handled identically, and
we do not think that this might have introduced any bias. In
addition, it might be argued that double centrifugation
decreases preanalytical inﬂuences in case of freezing. How-
ever, aiming to compare two different (single) centrifugation
schemes we did not apply double centrifugation for the
purpose of this study. We do not believe that this might
have introduced any bias. Seventh, plasma pathologically
enriched with soluble ﬁbrin might entrap VWF/FVIII by its
complexes and technically diminish these levels under low
temperature conditions. The risk of a systematic bias is low
however, because both pairs of samples were treated
identically.
We believe that our results add sufﬁcient data on previous
studies to justify rapid centrifugation for routine hemostasis
tests (PT, thrombin time, aPTT, ﬁbrinogen, D-dimer, anti-
thrombin, and anti-Xa activity). Traditional centrifugation
schemes shall be used for all other tests. The problem of
sample identiﬁcation can be solved by means of different
adhesive labels (“routine” vs. “specialized hemostasis”) or by
means of laboratory automation procedures as done in our
institution (samples with certain tests requested will be put
out of the laboratory track for “manual centrifugation”).
Fig. 3 Accuracyof routinehemostasismeasurements obtainedwith a rapid, high-speedcentrifugation scheme. Spearman’s rankcorrelation coefﬁcient (rs)
is contrasted tothecoverageprobability (CPπ) at agivenacceptable total deviation indexκof0.15.Theacceptable rswas set at 0.95, and theacceptableCPπ
at 0.9. aPTT, activated partial thromboplastin time; INR, international normalized ratio; LMWH, lowmolecular weight heparin; PR, prothrombin ratio; UFH,
unfractionated heparin; VWF:Ag, von Willebrand factor antigen; VWF:GPIbM, von Willebrand factor activity.
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Conclusion
Wetestedtheaccuracyofmeasurementsobtainedwitha rapid,
high-speedcentrifugation schemestudyinga largespectrumof
hemostasis tests and covering the full spectrum of values
obtained in clinical practice. The new agreement measure CP
π identiﬁed more assays with nonconcordant results than
Spearman’s correlation coefﬁcient. A clinically appropriate
concordance between measurements was observed for all
routine parameters, but relevant discrepancies were observed
with regard tomost single-factordeterminations aswell as von
Willebrand activity. We believe that our results add sufﬁcient
data on previous studies to justify rapid centrifugation for
routine hemostasis tests (PT, thrombin time, aPTT, ﬁbrinogen,
D-dimer, antithrombin, and anti-Xa activity). A traditional
centrifugation scheme shall be used for all other tests.
What is known about this topic?
• Short and uniform centrifugation schemes contribute
signiﬁcantly to successful laboratory automation.
• To date, it is unclear if this is applicable to the hemo-
stasis laboratory.
What does this paper add?
• We assessed a rapid, high-speed centrifugation
scheme in a large set of hemostasis tests, covering
the full spectrum of values obtained in clinical prac-
tice, and using meaningful statistical measures.
• We demonstrated that high-speed centrifugation is
applicable to the majority of routine hemostasis
parameters.
• The coverage probability was more sensitive than
Spearman’s rank correlation to detect disagreement
among centrifugation schemes.
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